1Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice.J Clin Pathol,2005,58:308-312.
2Jacobs I. Discussion:ovarian cancer screening. Gynecol Oncol,2003,88:80-83.
3Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002, 359(9306): 572-577.
4Kozak KR, Amneus MW, Pusey SM,et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.Proc Natl Acad Sci U S A, 2003,100:12343-12348.
5Kalofonos HP, Giannakenas C, Kosmas C, et al. Radioimmunoscintigraphy in patients with ovarian cancer. Acta Oncol,1999,38:629-634.
6Lieberman G, Buscombe JR, Hilson AJ, et al. Preoperative diagnosis of ovarian carcinoma with a novel monoclonal antibody.Am J Obstet Gynecol,2000,183:534-540.
7Wilder JL, Pavlik E, Straughn JM,et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol,2003,89:233-235.
8Topuz E, Aydiner A, Saip P, et al. Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer.Eur J Gynaecol Oncol,2000,21:599-602.
9Yeh LS, Hung YC, Kao A, et al. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.Anticancer Res,2002,22:3669-3671.
10Pannu HK, Horton KM, Fishman EK. Thin section dual-phase multidetector-row computed tomography detection of peritoneal metastases in gynecologic cancers.J Comput Assist Tomogr,2003,27:333-340.
